Gsa Capital Partners LLP Igm Biosciences, Inc. Transaction History

Gsa Capital Partners LLP

$1.43 Billion
Q2 2025

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 08, 2025	BUY	$1.15 - $6.8 $381,594 - $2.26 Million	331,821 Added 354.96%	425,303 $489,000
Q4 2024 Feb 07, 2025	BUY	$6.05 - $17.83 $222,204 - $654,860	36,728 Added 64.71%	93,482 $571,000
Q3 2024 Nov 05, 2024	SELL	$6.28 - $17.68 $32,825 - $92,413	-5,227 Reduced 8.43%	56,754 $939,000
Q2 2024 Aug 15, 2024	BUY	$6.51 - $11.47 $283,725 - $499,897	43,583 Added 236.89%	61,981 $426,000
Q1 2024 May 03, 2024	BUY	$8.68 - $17.36 $159,694 - $319,389	18,398 New	18,398 $177,000
Q3 2023 Nov 15, 2023	BUY	$6.66 - $10.64 $175,544 - $280,449	26,358 Added 24.65%	133,276 $1.11 Million
Q2 2023 Aug 14, 2023	BUY	$8.86 - $14.0 $529,234 - $836,262	59,733 Added 126.59%	106,918 $986,000
Q1 2023 May 12, 2023	BUY	$13.74 - $25.76 $238,031 - $446,266	17,324 Added 58.02%	47,185 $648,000
Q4 2022 Feb 13, 2023	BUY	$15.45 - $26.02 $180,486 - $303,965	11,682 Added 64.26%	29,861 $508,000
Q3 2022 Nov 14, 2022	SELL	$15.42 - $27.01 $57,639 - $100,963	-3,738 Reduced 17.06%	18,179 $413,000
Q2 2022 Aug 09, 2022	SELL	$13.27 - $25.5 $193,742 - $372,300	-14,600 Reduced 39.98%	21,917 $395,000
Q1 2022 May 11, 2022	BUY	$13.42 - $29.73 $387,126 - $857,621	28,847 Added 376.1%	36,517 $976,000
Q4 2021 Feb 14, 2022	BUY	$27.59 - $66.39 $62,491 - $150,373	2,265 Added 41.91%	7,670 $225,000
Q3 2021 Nov 12, 2021	BUY	$65.76 - $90.65 $33,471 - $46,140	509 Added 10.4%	5,405 $355,000
Q2 2021 Aug 05, 2021	BUY	$57.98 - $96.6 $61,690 - $102,782	1,064 Added 27.77%	4,896 $407,000
Q1 2021 May 10, 2021	SELL	$71.56 - $121.23 $194,571 - $329,624	-2,719 Reduced 41.51%	3,832 $294,000
Q4 2020 Feb 03, 2021	BUY	$47.41 - $115.03 $310,582 - $753,561	6,551 New	6,551 $578,000

Others Institutions Holding IGMS

# of Institutions

Shares Held

15.8M

Call Options Held

26.8K

Put Options Held

800

View Full List

About IGM Biosciences, Inc.

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $36.8M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

More about IGMS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account